Merck and Moderna announced Phase 3 results for a personalized mRNA vaccine, Intismeran Autogene, given alongside the immunotherapy drug Pembrolizumab to 1,137 high-risk melanoma patients after tumor removal surgery. Over an average 24.6-month follow-up, the combination reduced recurrence or death risk by 42% and metastasis risk by 38% compared with Pembrolizumab alone, with 82.2% of combination-treatment patients remaining recurrence-free versus 70% on Pembrolizumab alone.
wired.com
· 2026-10-24
Moderna and Merck said their experimental melanoma vaccine showed strong results in a late-stage clinical trial, nearly halving patients' risk of cancer recurrence or death. The companies are now preparing to seek regulatory approval, with the treatment potentially reaching patients as early as 2027.
fastcompany.com
· 2026-10-23
Merck and Moderna released full results from a trial of their personalized mRNA melanoma vaccine earlier than planned, after details apparently leaked. The companies reported that 82% of patients who received the vaccine alongside Keytruda remained cancer-free two years later.
gizmodo.com
· 2026-10-23
A phase III trial of 1,137 melanoma patients found that intismeran, a personalized mRNA vaccine developed by Moderna and Merck, reduced the risk of cancer recurrence or death by 42% when given alongside an immunotherapy drug after tumour-removal surgery. The companies released key results early after trial data leaked online ahead of their scheduled presentation at a European oncology conference in Madrid on 24 October.
nature.com
· 2026-10-23
Moderna and Merck announced that their personalized mRNA melanoma vaccine, combined with Merck's Keytruda, reduced the risk of death or cancer recurrence by 42% compared to Keytruda alone in a Phase 3 trial of 1,137 patients with stage IIB-IV melanoma. The companies released top-line results early after an oncology news outlet broke an embargo ahead of a scheduled presentation at the European Society of Medical Oncology conference in Madrid, with full data set for publication in the New England Journal of Medicine.
arstechnica.com
· 2026-10-22
Moderna's shares fell as much as 25% after partial trial results for its personalized melanoma vaccine, developed with Merck, leaked ahead of the official release. The full data showed the vaccine combined with Merck's Keytruda cut recurrence or death risk by 42% versus Keytruda alone, with 82% of patients cancer-free at two years compared to 70% on Keytruda alone.
slashdot.org
· 2026-10-22
As Moderna and Merck develop personalized cancer therapies, data and diagnostics firm Tempus AI is emerging as a key infrastructure player supporting that work. Personalis, a genomic testing company, sits at the center of this positioning, suggesting a broader supply-chain opportunity beyond the drugmakers themselves.
wsj.com
· 2026-09-04
Jim Cramer highlighted August as a recovery month for several S&P 500 stocks that had been beaten down by fears over AI disruption and slowing growth. Moderna topped the index after positive melanoma vaccine data with Merck, while enterprise software names like Palantir, Salesforce, ServiceNow and Veeva rebounded as earnings and product results eased investor doubts. Cramer noted that some of the earlier declines were worsened by a hedge fund, Situational Awareness, forced to unwind large bearish software bets in late July.
cnbc.com
· 2026-08-31
A phase III trial of intismeran, a personalized cancer vaccine developed by Merck and Moderna, showed that melanoma patients who received it had longer recurrence-free survival than those given a placebo. The double-blind study of more than 1,100 participants builds on an earlier phase II trial with 157 patients and moves the vaccine closer to regulatory approval.
nature.com
· 2026-08-28
Singer Dolly Parton has died at age 80, remembered for her philanthropic contributions to science alongside her music career. She provided early funding for Moderna's vaccine research and publicly received her own COVID-19 vaccination to counter public hesitancy, while her Imagination Library program continues distributing over three million books monthly to children worldwide.
nature.com
· 2026-08-26
GoKawiil